Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

NCT04927585 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: env (A,B,C,A/E)/gag (C) DNA Vaccine
BIOLOGICAL: gp120 (A,B,C,A/E) Protein Vaccine
BIOLOGICAL: GLA-SE adjuvant
BIOLOGICAL: Placebo

Sponsor

Worcester HIV Vaccine

Collaborators

[object Object]
[object Object]